Biosyent Inc (BIOYF) 6.3800 $BIOYF BioSyent Comments on

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Biosyent Inc (BIOYF) 6.3800 $BIOYF

BioSyent Comments on Recent Market Activity
Marketwired - Fri Apr 10, 7:01AM CDT
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) wishes to comment on the unusual recent market activity in its stock. The Company advises that it is not aware of any material undisclosed business development that should account for the decrease in its stock price on Thursday, April 9, 2015. The Company looks forward to disclosing its first quarter results on May 13, 2015.
RX.VN: 8.130 (+0.720)

BioSyent Pharma Announces the Canadian Launch of the First of 3 New Products Using the Patented Aguettant System(R)
Marketwired - Tue Feb 03, 7:05AM CST
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of the Aguettant System(R) for pre-filled syringes (PFS), a new urgent care product for use in hospitals and acute care settings.
RX.VN: 8.130 (+0.720)

BioSyent Pharma Launches New Proktis-M(R) Suppositories
Marketwired - Mon Nov 24, 7:07AM CST
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) today announced that its subsidiary BioSyent Pharma Inc. has commenced the Canadian launch of Proktis-M(R) suppositories.
RX.VN: 8.130 (+0.720)

BioSyent Releases Q3 and Nine Month Results-Q3 Sales Increase 56%, Net Income Up 64%; Nine Month Sales Up 62%, Net Income Up 75%
Marketwired - Mon Oct 20, 7:06AM CDT
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) released today a summary of its Third Quarter (Q3 2014) and nine months financial results for the three and nine months ending September 30, 2014. Key highlights include:
RX.VN: 8.130 (+0.720)

BioSyent Releases Q2 and Six Month Results-Q2 Sales Increase 72%, Net Income After Tax Up 112%
Marketwire - Thu Aug 21, 7:03AM CDT
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) released today a summary of its Second Quarter (Q2 2014) and first half (H1 2014) financial results for the three and six months ending June 30, 2014. Key highlights include:
RX.VN: 8.130 (+0.720)

BioSyent Pharma Signs Exclusive Licensing and Distribution Agreement For New Urgent Care Drug Product
Marketwire - Wed Jul 23, 8:44AM CDT
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) is pleased to announce that its subsidiary BioSyent Pharma Inc. has signed an exclusive Licensing and Distribution Agreement with an existing European partner for a new product that will be marketed by its' Hospital Products Division. The new product utilizes a patented delivery system that offers technical advantages over existing alternatives and will be used in hospitals and acute care settings. These products will provide hospitals, clinics, and healthcare professionals with improved patient safety as well as operational efficiencies. The product will be launched after Health Canada approval.
RX.VN: 8.130 (+0.720)

BioSyent Inc. (TSXV:RX) is the Subject of StockPotentials Report by eResearch Corp - Video Summary of Report Posted on www.investmentpitch.com
Thomson Reuters ONE - Mon Jul 07, 6:28PM CDT
Vancouver, BC, July 7, 2014 - Toronto based eResearch has issued a StockPotentials report on BioSyent Inc. (TSXV:RX), a Toronto-based, growth oriented, independent pharmaceutical company. StockPotentials reports cover smaller companies eResearch believes would be primarily of interest to retail investors.
RX.VN: 8.130 (+0.720)

eResearch Issues Stock Potentials Report on BioSyent Inc.
ACCESSWIRE - Thu Jul 03, 10:51AM CDT
Toronto, ON / ACCESSWIRE / July 3, 2014 / eResearch Corporation provides Stock Potentials reports to highlight interesting prospects which may benefit from the exposure that eResearch can provide through its extensive electronic distribution network. This latest report features BioSyent Inc., a growth-oriented specialty pharmaceutical company, based in Toronto.
RX.VN: 8.130 (+0.720)

BioSyent to Present at the 2014 Bloom Burton & Co. Healthcare Investor Conference
Marketwire - Fri Jun 13, 4:13PM CDT
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) is pleased to announce that CEO Rene Goehrum will be making a presentation at the 2014 Bloom Burton & Co. Healthcare Investor Conference at 4:30pm (ET), June 18, 2014 at the Toronto Board of Trade. Mr. Goehrum will provide an overview of the Company and its corporate activities.
RX.VN: 8.130 (+0.720)

BioSyent Named to the PROFIT 500 Ranking of Canada's Fastest-Growing Companies with a 5 year Revenue Growth Rate of 608%
Marketwire - Thu Jun 12, 3:02PM CDT
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) is pleased to announce that Canadian Business and PROFIT has ranked BioSyent as one of Canada's Fastest-Growing Companies in the just released 2014 rankings. Published in the July issue of Canadian Business and online at PROFITguide.com, the PROFIT 500 ranks Canadian businesses by their revenue growth over five years. Based upon a five year revenue (2008-2013) growth rate of 608%, BioSyent ranked 104 on the PROFIT 500 list. This is the second consecutive year that BioSyent has been named to the Profit 500 list and marks a significant increase in 5 year growth rate, from 355% on last year's list to 608% on this year's list.
RX.VN: 8.130 (+0.720)

BioSyent Pharma Receives Health Canada Approval to Market New Urgent Care Product
Marketwire - Thu Jun 12, 7:03AM CDT
BioSyent Inc. ("BioSyent" (TSX VENTURE: RX) is pleased to announce that its subsidiary BioSyent Pharma Inc. has received Health Canada - Therapeutics Products Directorate approval to market a new urgent care product. This is the first of two products that were in-licensed from a European partner and submitted to Health Canada in 2013 for approval.
RX.VN: 8.130 (+0.720)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

Updated Category News Views 393

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

Continue Reading
Invasive Procedures Don't Extend Life in Stable Heart Disease

Updated Category News Views 220

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...

Continue Reading
Quantum Space Joins $185M NASA Lunar Transport Deal

Updated Category News Views 298

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 110

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
Aurora Innovation Faces Legal Heat Amid Delays

Updated Category News Views 150

Production Snags at Aurora Innovation Ah, investing – not for the faint-hearted. One day you're riding high, the next you're scraping by, and Aurora Innovation's (NASDAQ:AUR) investors just hit a rough patch. The autonomous trucking darling announced unexpected delays in its delivery schedule, sending shockwaves through its stock price and shaking investor confidence....

Continue Reading
Johnson & Johnson Unveils Promising PsA Treatment Data

Updated Category News Views 188

A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...

Continue Reading
Evaluating GLP-1 Telehealth? Key Questions to Consider

Updated Category News Views 331

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Continue Reading
Off-Broadway Play 'DUST' Raises Autism Support Funds

Updated Category News Views 318

Here's the scoop: an Off-Broadway production just did something many big hitters can't pull off. 'DUST,' a show crafted like a love letter to the American West, managed to rustle up $30,000 for young adults grappled with autism. Partnering with no less than Yale's Cultural Autism Studies and the Ed Asner Family Center, this effort hit the mark in more ways than one. An...

Continue Reading
ecozy's Brezzano Switch: Brewing Simplicity at Home

Updated Category News Views 361

Breathe the aroma, sip the innovation. ecozy just threw their Brezzano Switch into the arena, and here's the deal: it's a no-nonsense, get-your-caffeine-fix kind of machine aimed at making your mornings simple without compromising on flavor. Unique Features of the Brezzano Switch So, what's cooking? Get this—it's not just any coffee contraption. Built sleek and compact,...

Continue Reading
Adding Fireplaces: Home Comfort or Construction Headache?

Updated Category News Views 227

Sizing Up the Installation Options Slapping a fireplace into a home sounds more like a pipe dream than a practical project for most folks. But according to fireplace whiz Jimmy Smith down in North Charleston, the times are a-changin'. These days, with advances in technology, homeowners can actually pull it off without collapsing their living room walls. Nitty-Gritty:...

Continue Reading

Top 5 Most Recently Viewed Articles

Carrier's $2.5 Million Commitment for Wildfire Relief Efforts

Updated Category News Views 244

Carrier's Generous Pledge for Wildfire Relief In a significant initiative aimed at supporting communities affected by wildfires, Carrier Global Corporation (NYSE: CARR), a leader in intelligent climate solutions, has announced its commitment to donate over $2.5 million worth of indoor air purifiers. This effort is specifically directed towards enhancing air quality for...

Continue Reading
Lundbeck Unveils New Insights on Multiple System Atrophy

Updated Category News Views 358

Lundbeck Reveals Insights into Multiple System Atrophy at International Congress VALBY, Denmark – H. Lundbeck A/S (Lundbeck) is set to present pivotal pipeline data and invaluable patient perspectives from the recent AMULET trial, highlighting amlenetug as a promising treatment for the rare neurological disorder known as multiple system atrophy (MSA). This significant...

Continue Reading
Keenova Therapeutics: A New Era for Mallinckrodt's Spin-Off

Updated Category News Views 599

Welcome to Keenova Therapeutics In an exciting announcement, Mallinckrodt plc has successfully completed the planned spin-off of its Par Health generic pharmaceuticals and sterile injectables businesses. As of now, the company will operate under the new name, Keenova Therapeutics, dedicating its efforts towards developing and delivering innovative therapies for patients...

Continue Reading
BlackRock, Inc. Increases Shareholding in Ageas to 7.78%

Updated Category News Views 154

Recent Financial Developments at Ageas In an important disclosure regarding financial transparency, BlackRock, Inc. has officially notified Ageas that it has exceeded the legal threshold of 5% ownership in the company, with its current shareholding reaching an impressive 7.78%. This notification was made in accordance with regulatory requirements aimed at maintaining...

Continue Reading
AKWEL Reports Revenue Decline in Nine-Month Financial Update

Updated Category News Views 48

Decline in Revenue for AKWEL in Recent Financial Update AKWEL, a key player in the automotive and heavy-vehicle parts market, has announced a notable decline in their financial performance for the first nine months of the year. The company, specializing in fluid management and structural parts for electric vehicles, has reported a consolidated revenue of €757.7 million,...

Continue Reading